title: Predictors of nonadherence to single-dose nevirapine therapy for the prevention of mother-to-child HIV transmission.
abstract: BACKGROUND
  Adequate adherence is required for prevention of mother-to-child transmission of HIV (pMTCT) programs to be effective. We investigated predictors and extent of nonadherence to single-dose nevirapine.
  
  
  METHODS
  Data on nevirapine intake and possible predictors were collected among 760 HIV-positive women with liveborn babies enrolled in a study in Lusaka, Zambia.
  
  
  RESULTS
  Most (94%) women took nevirapine before delivery, and most (91%) newborns received it soon after delivery. Maternal nonadherence was associated with home births (odds ratio [OR]: 3.2; 95% confidence interval [CI]: 1.3 to 7.4), no high school education (OR: 2.4; 95% CI: 1.1 to 5.3), and low newborn birth weight (OR: 4.6; 95% CI: 1.3 to 20.1). Disclosure of HIV status and couples counseling was only associated with adherence among home births. Failure to administer nevirapine to the newborn was associated with birth at the tertiary hospital (OR: 7.2; 95% CI: 3.7 to 13.8), lower 5-minute Apgar scores (OR: 0.5; 95% CI: 0.4 to 0.7), and neonatal death (OR: 5.8; 95% CI: 2.0 to 16.3).
  
  
  CONCLUSIONS
  Excellent adherence to single-dose nevirapine for pMTCT can be achieved. Nonadherence seems to be affected by place of birth and by poor health status of the newborn. Procedures to ensure that viable yet ill neonates receive nevirapine should be part of clinical protocols and training within pMTCT programs.
authors.affiliation: Gertrude H. Sergievsky Center, Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA.
authors.forename: Sandra
authors.initials: S
authors.lastname: Albrecht
authors.forename: Katherine
authors.initials: K
authors.lastname: Semrau
authors.forename: Prisca
authors.initials: P
authors.lastname: Kasonde
authors.forename: Moses
authors.initials: M
authors.lastname: Sinkala
authors.forename: Chipepo
authors.initials: C
authors.lastname: Kankasa
authors.forename: Cheswa
authors.initials: C
authors.lastname: Vwalika
authors.forename: Grace M
authors.initials: GM
authors.lastname: Aldrovandi
authors.forename: Donald M
authors.initials: DM
authors.lastname: Thea
authors.forename: Louise
authors.initials: L
authors.lastname: Kuhn
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D005260:Female; D006700:Home Childbirth / Q000706:statistics & numerical data; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008297:Male; D008423:Maternal Age; D019829:Nevirapine / Q000627:therapeutic use*; D016017:Odds Ratio; D010298:Parity; D010349:Patient Compliance; D010353:Patient Education as Topic; D011237:Predictive Value of Tests; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000821:virology*; D016312:Treatment Refusal; D014342:Truth Disclosure; D014881:Water Supply; D015024:Zambia
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine